ArticleEuropean journal of medicinal chemistry2012
Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.
Article in European journal of medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 83 citations in OpenAlex.
- Affinity Enhancement in Discrete Multivalent MegaMolecules.Chembiochem : a European journal of chemical biology · 2026Article
- Engineering pH-Responsive Dendrimer-STAT3 Inhibitor Conjugates for Intracellular Delivery.Biomacromolecules · 2026Article
- Article
- Highly regioselective 6-RSC advances · 2023Article
- Synthesis of Two Methotrexate Prodrugs for Optimizing Drug Loading into Liposomes.Pharmaceutics · 2021Article
- Immunomodulatory potential of anticancer therapy composed of methotrexate nanoconjugate and dendritic cell‑based vaccines in murine colon carcinoma.Oncology reports · 2021Article
- Toxic Effects of Methotrexate on Rat Kidney Recovered by Crocin as a Consequence of Antioxidant Activity and Lipid Peroxidation PreventionIranian biomedical journal · 2020Article
- Anti-leukemia activity of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Targeting Groups Employed in Selective Dendrons and Dendrimers.Pharmaceutics · 2018Review
- Distributions: The Importance of the Chemist's Molecular View for Biological Materials.Biomacromolecules · 2018Review
- Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles.International journal of nanomedicine · 2017Article
- Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.Advanced pharmaceutical bulletin · 2016Review
- Methotrexate Nanoparticles Prepared with Codendrimer from Polyamidoamine (PAMAM) and Oligoethylene Glycols (OEG) Dendrons: Antitumor Efficacy in Vitro and in Vivo.Scientific reports · 2016Article
- Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery.International journal of molecular sciences · 2015Review
- The therapeutic effect of methotrexate-conjugated Pluronic-based polymeric micelles on the folate receptor-rich tumors treatment.International journal of nanomedicine · 2015Article
- Poly(amidoamine) dendrimer-methotrexate conjugates: the mechanism of interaction with folate binding protein.Molecular pharmaceutics · 2014Article
- Nanodrug delivery in reversing multidrug resistance in cancer cells.Frontiers in pharmacology · 2014Review
- Design and exploratory data analysis of a second generation of dendrimer prodrugs potentially antichagasic and leishmanicide.Molecular diversity · 2013Article
- Avidity modulation of folate-targeted multivalent dendrimers for evaluating biophysical models of cancer targeting nanoparticles.ACS chemical biology · 2013Article
- Paclitaxel-conjugated PAMAM dendrimers adversely affect microtubule structure through two independent modes of action.Biomacromolecules · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Cancer-targeting drug delivery can be based on the rational design of a therapeutic platform. This approach is typically achieved by the functionalization of a nanoparticle with two distinct types of molecules, a targeting ligand specific for a cancer cell, and a cytotoxic molecule to kill the cell. The present study aims to evaluate the validity of an alternative simplified approach in the design of cancer-targeting nanotherapeutics: conjugating a single type of molecule with dual activities to nanoparticles, instead of coupling a pair of orthogonal molecules. Herein we investigate whether this strategy can be validated by its application to methotrexate, a dual-acting small molecule that shows cytotoxicity because of its potent inhibitory activity against dihydrofolate reductase and that binds folic acid receptor, a tumor biomarker frequently upregulated on the cancer cell surface. This article describes a series of dendrimer conjugates derived from a generation 5 polyamidoamine (G5 PAMAM) presenting a multivalent array of methotrexate and also demonstrates their dual biological activities by surface plasmon resonance spectroscopy, a cell-free enzyme assay, and cell-based experiments with KB cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.